IMPORTANCE Diagnostic screening for Anderson-Fabry cardiomyopathy (AFC) is performed in the presence of specific clinical red flags in patients with hypertrophic cardiomyopathy (HCM) older than 25 years. However, left ventricular outflow tract obstruction (LVOTO) has been traditionally considered an exclusion criteria for AFC.
A nderson-Fabry disease (AFD) is an X-linked lysosomal storage disease, characterized by decreased or absent activity of lysosomal α-galactosidase A due to a pathogenic mutation in the α-galactosidase A gene (GLA A). 1 As a result of α-galactosidase A deficiency, globotriaosylceramide (GL-3) and other glycosphingolipids are stored in various tissues, including kidney, heart, and skin tissues.
2 The diagnosis of AFD is challenging and often delayed up to 20 years following the onset of symptoms. [2] [3] [4] About 70% of patients with AFD show heart involvement, including left ventricular hypertrophy (LVH) , that may be severe and mimic hypertrophic cardiomyopathy (HCM). Anderson-Fabry cardiomyopathy (AFC) is common in male patients with the specific late-onset GLA variant p.Asn215Ser. 5 While common in HCM, resting left ventricular outflow tract obstruction (LVOTO) is rare in AFD and is more often associated with provokable gradients. 6 Therefore, basal LVOTO in HCM is usually considered an exclusion criteria for AFC. 7 We report a small series of severely symptomatic patients with AFD diagnosed with HCM and severe resting LVOTO who underwent surgical myectomy (SM). In each patient, the correct diagnosis was suspected intraoperatively by the cardiac surgeon and subsequently confirmed by histology and genetic analysis.
Methods

Study Population
From July 2013 to December 2016, 235 consecutive patients with a clinical diagnosis of obstructive HCM underwent SM in Policlinico di Monza, Monza, Italy, and Spitalul Hospital Monza, Bucharest, Romania, by the same senior surgeon (P.F.). In 3 patients (1.2%), the cardiac surgeon suspected a storage disease while inspecting the heart samples extracted from myectomy. The diagnosis of HCM was based o n c u r r e nt 2 0 1 4 E u r o p e a n S o c i e t y o f C a rd i o l o g y guidelines.
8 Specific cardiac diagnostic red flags for HCM phenocopies were evaluated in all patients, including specific signs of AFC, such as short P-R interval or heart block, concentric LVH and right ventricular hypertrophy, or late gadolinium enhancement (LGE) on the basal posterolateral LV wall on cardiovascular magnetic resonance. 8 Institutional review board approval was not needed for the study because it's a report of clinical practice.
Surgical Management
Patients were preoperatively evaluated and managed following standard of care. 7 Extended transaortic SM was performed with 2 longitudinal incisions in the basal septum 2 to 3 mm below the aortic valve and extended distally to the point of mitral septal contact, as previously described.
8,9
Histological Examinations and Genetic study
Myocardial samples collected during the surgery were examined by light microscopy following standard procedures. All patients gave informed consent for genetic analysis, which was focused on sarcomere genes associated with HCM and HCM phenocopies (PRKAG2, LAMP2, GLA, TTR, and RASopathiesrelated genes).
7
Results
Baseline Characteristics
The mean (SD) age at HCM diagnosis was 42 (4) years; all were male. None of the 3 patients presented with extracardiac features suggestive of AFD. Patient 1 was diagnosed after being resuscitated from cardiac arrest, with subsequent implantable cardioverter defibrillator implantation. He had no family history of sudden cardiac death, but his brother previously received a clinical diagnosis of nonobstructive HCM ( Figure 1 ). Patient 2 was diagnosed after syncope on exertion; family screening showed mildly obstructive HCM in the mother (aged 76 years). Patient 3 was diagnosed with HCM during routine evaluation for hypertension ( Figure 1 ). All patients reported dyspnea and angina, and both patients 2 and 3 had a history of syncope. All were in sinus rhythm at surgery, but patients 1 and 2 had a history of paroxysmal atrial fibrillation. All patients showed diffuse and asymmetrical LVH, with maximal 
Surgical Procedures
The mean (SD) age at the time of surgery was 63 (5) years. Mean (SD) resection samples weighed 9.6 (5.2) g and were yellowish ( Figure 2D ). On tactile sensation, the surgeon felt a spongy consistency of the surgical samples, different from the usual stony-elastic feel typical of classic HCM, and this prompted histological examinations. The immediate postoperative course was uneventful for patients 1 and 2. Patient 3 experienced 2 self-terminating episodes of atrial fibrillation and 2 runs of nonsustained ventricular tachycardia. Mean (SD) septal thickness after surgery was 19 (3) mm compared with 27 (5) mm before surgery (Table) .
Histology and Genetic Analysis
Histological examinations showed evidence of intracellular storage with prominent cytoplasmatic vacuolization of the myocytes in all patients. Genetic analysis showed the cardiac AFD variant GLA A gene mutation p.Asn215Ser in all 3 patients ( Figure 1 ). In addition, patient 1 also had an MYBPC3 variant of unknown significance (p.Arg733Leu), which did not segregate into the family.
Clinical and Hemodynamic Benefit
All patients experienced substantial symptomatic and hemodynamic improvement after surgery (Table) . At a mean (SD) postoperative follow-up of 33 (14) months, the outcome was excellent, with patients 2 and 3 reporting complete abolition of symptoms, and patient 1 improving to New York Heart Association class II. The peak basal LVOT gradient was reduced from a mean (SD) of 97 (20) mm Hg before surgery to 10 (7) mm Hg after surgery. No ventricular arrhythmias occurred, and only 1 episode of atrial fibrillation requiring electrical cardioversion was experienced by patient 1. Patients 1 and 2 refused enzyme replacement therapy, whereas patient 3 has been treated with α-galactosidase for 10 months, unassociated with further reduction in LVH.
Discussion
The diagnosis of AFD represents an important clinical challenge for the physician because of the heterogeneity of phenotypic manifestations. 2 Anderson-Fabry cardiomyopathy has been reported in 0.5% to 2% of adult patients with HCM but up to 4% in male patients with HCM older than 40 years owing to the progressive development of LVH in men after age 25 years. 1, 4, 10 The implications of a delayed or neglected diagnosis are considerable because patients are denied the opportunity of enzyme replacement therapy and cascade family screening. 1 Cardiologists should look for specific cardiac and extracardiac signs that raise the suspicion of AFC, such as proteinuria or neuropathic pain. 11 However, none of these may be present when the heart is the only organ involved. 6 We report a series of patients with AFD in whom asymmetric LVH and basal LVOTO, traditionally considered 2 exclusion criteria for AFC, were the distinctive features, in the absence of any cardiac and extracardiac red flags. Specifically, no patients presented with sinus bradycardia or electrocardiographic features suggestive of AFC, and LGE was present in only 1 patient in an atypical site for AFC. 6 Of note, to our knowledge, SM has only been previously reported in 6 patients with symptomatic AFC, of whom 2 had provokable LVOTO 5 and 4 had resting LVOTO. [12] [13] [14] As in this series, all experienced symptomatic and hemodynamic relief after surgery, 5,12-14 and unlike alcohol septal ablation, SM has allowed direct histological examination of the surgical specimen. To the best of our knowledge, we document for the first time a suspicion of AFC raised intraoperatively by the cardiac surgeon, based on the peculiar yellowish appearance of the myocardium and its spongy consistency and directly leading to diagnosis by subsequent histological and genetic analysis. Indeed, although up to 50% of patients with AFC may show inducible LVOTO during exercise, 5 a small subset of patients with AFC may present with basal LVOTO.
12-14
Before surgery, none of the patients had completed genetic testing, which has a class I indication according to the 2014 European Society of Cardiology HCM guidelines.
7 Contemporary next-generation sequencing panels for HCM should always include GLA, TTR, PRKAG2, LAMP2, and all potential phenocopies genes, including RASopathies. 15 Indeed, sarcomeric gene mutations of unknown significance are common and may be misleading when incomplete gene panels are tested, as would have been the case in patient 1 had GLA not been tested.
Conclusions
In this consecutive surgical series, AFC prevalence was 1.2%.
Features that are often-and erroneously-considered to exclude AFC, such as asymmetric LVH and resting LVOTO, may indeed be part of its phenotypic spectrum. Here, the diagnosis was suspected by the cardiac surgeon and confirmed by histological and genetic examinations. Thus, genetic screening for AFC, as part of contemporary nextgeneration sequencing panels including other rare HCM mimics, should be routinely performed in patients with HCM, even in the absence of cardiac and noncardiac red flags for AFC.
